Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-group, Randomized, Open-label Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D.

NCT06505928 is registered in ClinicalTrials.gov with Shanghai HEP Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06505928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06505928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-group, Randomized, Open-label Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D.
Lead sponsor
Shanghai HEP Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 11, 2024
Completion date
July 31, 2026
Enrollment
90 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis d